Crispr Therapeutics initiated with a Buy at Mizuho

Mizuho analyst Salim Syed initiated coverage of Crispr Therapeutics with a Buy rating and $82 price target. Genentech is “often regarded as one of the world’s most successful (and first) biotech companies” and Crispr often mentions that it aspires to be the “next Genentech,” though “the notion seemingly often gets disregarded by the market near automatically,” the analyst tells investors. However, the firm tried to answer whether it’s possible for Crispr to be the “next Genentech”, not just due to a nearing expected first approval, and “ultimately landed that the notion is worth more consideration than the market seems to ascribe,” the analyst added.